Can MetroCity Bankshares bounce back? Q3 2024 results reveal slight profit slip

Can MetroCity Bankshares bounce back? Q3 2024 results reveal slight profit slip

MetroCity Bankshares, Inc. (NASDAQ: MCBS), the holding company for Metro City Bank, has disclosed its financial performance for the third quarter of 2024. The report highlights a net income of $16.7 million, equivalent to $0.65 per diluted share. Although this figure is slightly below the $16.9 million or $0.66 per diluted share recorded in the […]

Home Bancorp Inc’s shocking Q3 surge: Profits soar and dividend boosted by 4%—Investors rejoice

Home Bancorp Inc’s shocking Q3 surge: Profits soar and dividend boosted by 4%—Investors rejoice

Home Bancorp, Inc. (Nasdaq: “HBCP”), the parent company of Home Bank, N.A., has reported robust financial results for the third quarter of 2024, with a notable 4% increase in its quarterly dividend. The company announced a net income of $9.4 million or $1.18 per diluted share, an increase from $8.1 million or $1.02 per diluted […]

Virginia National Bankshares Corporation’s Q3 2024 earnings: A mixed bag of performance and strategic growth

Virginia National Bankshares Corporation’s Q3 2024 earnings: A mixed bag of performance and strategic growth

Virginia National Bankshares Corporation, trading on NASDAQ under the symbol VABK, has reported its earnings for the third quarter of 2024. The company’s net income stood at $4.6 million, translating to $0.85 per diluted share. This marks a slight dip from the $4.7 million, or $0.86 per diluted share, posted in Q3 of 2023. Over […]

Ceribell’s stock surges 36% in blockbuster trading debut: AI seizure tech takes Wall Street by storm

Ceribell’s stock surges 36% in blockbuster trading debut: AI seizure tech takes Wall Street by storm

In a sensational opening on Wall Street, Ceribell’s stock surged by 36% in its trading debut, reflecting immense investor enthusiasm for the neurotech company’s AI-powered seizure detection technology. Ceribell priced its initial public offering (IPO) at $17 per share, the top of its proposed range, and quickly saw its valuation skyrocket as shares began trading […]

Biotech stocks in trouble? Immatics shares plunge after $150m funding news shocks investors

Biotech stocks in trouble? Immatics shares plunge after $150m funding news shocks investors

Immatics N.V. (NASDAQ: IMTX), a clinical-stage biopharmaceutical company focused on cancer immunotherapies, has seen its shares decline significantly after announcing a $150 million public offering. The announcement came as a surprise to investors, with the stock experiencing a sharp drop of approximately 10%, closing at $9.95 from its previous levels above $11. This downturn has […]

Immuron Limited reveals key findings from NMRC study, eyes future collaboration with U.S. DoD

Immuron Limited reveals key findings from NMRC study, eyes future collaboration with U.S. DoD

Immuron Limited has announced the results of a Campylobacter human infection model study conducted by the U.S. Naval Medical Research Command (NMRC). The Melbourne-based biopharmaceutical company, listed on the ASX (IMC) and NASDAQ (IMRN), focuses on developing oral immunotherapies for gut-mediated diseases, including its flagship product, Travelan. Recently, NMRC concluded an interim analysis of a […]

Banzai International’s stock skyrockets 96% after massive debt restructuring

Banzai International’s stock skyrockets 96% after massive debt restructuring

Banzai International experienced a dramatic 96% surge in its stock value, hitting $8.23 after announcing a substantial debt restructuring plan worth $24.8 million. This comes after the Seattle-based marketing technology company made a decisive move to tackle its financial burdens by restructuring its debt and extending its cash runway. The company’s shares had been down […]